RE:RE:RE:RE:RE:RE:RE:RE:Market Cap funLongholder99 wrote: Yes 15B may be too optimistic. However GBM will be a fast trial IMO. Simply because of the lethality of the condition and the fast degradation in quality of life once diagnosis comes. Usually well Into the diseases' development because people generally dont get the MRI until symptoms have started. By then the tumour(s) are well established. Once treated symptoms should diminish then disappear along with the tumors. Patients will hopefully respond remarkably and Ph1 will probably be stopped early just like NMIBC was. NMIBC will bring credibility. GBM will be the game changer.
I'm around 16B, two years out. In Lab With xray, they have bladder cell kill rate at 99.5%. With GBM, their current combination therapy is around 47%... I believe I've seen new compounds thrown around in the patents as well.. tld002, tld007.. if they find the right mix with GBM and proven track record with bladder,,, speculative valuation will come quickly because it will have no choice but to price in GBM, lung, cervical, you name it.